No Picture
News

Immunicom Secures an Additional $1.85 Million Bringing its Series B Funding to $12.85 Million

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ — Immunicom, Inc., a medical technology company that has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer, gained an additional $1.85 m… […]